Oncology Day One's big bet on tovorafenib just keeps paying off Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.